Eisai announced that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.

15 senior directors registered for eyeforpharma’s SFE 2011 (29-31 March, Dusseldorf) meeting. The Event Director Kate Eversole stated, “I am overwhelmed by the amount of interest for this show- we have already sold 1/3 of our tickets- mostly to large group from big pharma including – Abbott & Pfizer. However, we are getting increasing interest from some of the smaller generic companies” If it keeps selling at this rate we will sell out in our early bird next week!”

The next edition of PIA Vietnam, a premier trade event focused on process engineering and instrumentation as well as laboratory and scientific equipment, will be taking place at Saigon Exhibition & Convention Center (SECC), Ho Chi Minh City, from 23 to 25 March 2011.

Protagen AG, a specialist for GMP-compliant protein analysis and in-vitro diagnostics is presenting at the Personalized Medicine and Diagnostics Europe Congress in London. Dr. Stefan Müllner, CEO of Protagen AG will discuss the latest achievements in personalized medicine together with an expert panel of representatives from pharma, biotech and diagnostic.

Allan Mackintosh, PMAP Performance Coach, Gruenthal believes that the KAM approach is where we will see most change within the pharma industry over the next 5-10 years. It is undeniable that the customer base is more complex than ever before and with an increasingly restricted environment, the industry needs to change how it interacts with bodies such as the NHS and “KAM is the way forward”

ARIAD Pharmaceuticals, Inc. announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. Merck is currently developing ridaforolimus in multiple cancer indications under an exclusive license and collaboration agreement with ARIAD. Complete findings from the SUCCEED trial will be submitted for presentation at an upcoming medical meeting this year.